Related Experiment Video
Updated: Aug 10, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Valaciclovir for chronic hepatitis B virus infection after lung transplantation
I Laube1, A Boehler, E L Renner
1Dept. of Internal Medicine, University Hospital Zurich, Raemistr. 100, CH- 8091, Zurich, Switzerland. klinspr@usz.unizh.ch
Abstract:
We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation.
More Related Videos
Related Concept Videos
Herpes
Cytomegalovirus Disease
Hepatitis
Genital Herpes
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction

